India Plan To Fund Pharma R&D Meets Consumer Objections
This article was originally published in PharmAsia News
Executive Summary
An effort by the Indian government to contribute funds to help encourage more pharmaceutical research and development in the country has encountered objections from public interest groups. The government plan would allow drugs developed as a result of the funds to be patented. The groups say it is not fair to allow drugs developed with public money to be granted patents, saying the grant of a monopoly on marketing the drugs would cause them to be more expensive to the general public. (Click here for more
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.